Desk note · industry · Pharmaceuticals / GLP-1 generics
Dr Reddy’s expects to restart semaglutide supplies from November
Dr Reddy’s Laboratories told reporters on 23 October 2026 that it resolved active pharmaceutical ingredient issues that had disrupted semaglutide rollout earlier in the year and expects to resume supplies across key international markets from November, with Canada likely to account for much of the initial volume.

- •Management said on 23 October 2026 that manufacturing issues affecting semaglutide API were fixed and shipments should restart from November 2026.
- •Canada is expected to take the bulk of early volumes after the disruption slowed the company’s international generic rollout.
- •The update sits alongside September-quarter results where lower lenalidomide sales weighed on revenue even as underlying base business grew at double-digit rates.
What's going on here?
On 23 October 2026, Dr Reddy’s Laboratories Ltd told journalists it is on track to resume semaglutide supplies after resolving active pharmaceutical ingredient problems that had interrupted the product’s rollout earlier in 2026. Executives said shipments to key international markets should restart from November, with Canada likely to drive most of the first wave of volumes. Semaglutide is the molecule behind blockbuster GLP-1 therapies for diabetes and obesity; Indian manufacturers have been racing to supply licensed generic versions where patents allow. The supply restart update came as the company discussed September-quarter earnings, where revenue was pressured by falling lenalidomide sales even as management highlighted double-digit growth in the underlying base portfolio.
What does this mean?
API quality or scale issues can pause a high-profile launch even when demand and regulatory approvals are in place. Fixing the molecule supply chain unlocks revenue that was stuck in the factory rather than lost to rivals permanently. Canada as the lead market suggests Dr Reddy’s will stage volumes where pricing and channel partnerships are already cleared before widening to other geographies. For patients abroad on GLP-1 therapies, a reliable Indian generic supplier can ease shortages, but launch timing still depends on local approvals and distributor contracts. Investors will watch whether restarted sales lift margin mix in the second half of the fiscal year.
Why should I care?
If you follow Indian pharma exporters, treat semaglutide as a capacity and compliance story, not just a patent headline. Healthcare buyers outside India should track distributor notices for stock availability rather than assuming instant shelf presence. Competitors with their own GLP-1 filings may accelerate launches if Dr Reddy’s stumbles again. Watch November shipment disclosures, any US or Europe timeline commentary on earnings calls, and regulatory updates on obesity-label generics in India.
More desk notes
Markets / GIFT IFSC
GIFT Nifty open interest set a fresh record above $22 billion
NSE International Exchange said on 19 November 2026 that GIFT Nifty open interest reached $22.21 billion on 18 November, topping the prior October peak as offshore index contracts keep drawing hedging and speculative flow at GIFT City.
Financial services / broking
Fairfax now owns more than half of IIFL Capital Services
FIH Mauritius Investments bought an 11.8% block from promoters on 19 November 2026 for about ₹1,540 crore, lifting the Fairfax group's combined holding in IIFL Capital Services Ltd past 50% as it funds the IDBI Bank takeover.
Power transmission
Adani Energy won a Bihar link for a 2,400 megawatt power plant
Adani Energy Solutions Ltd secured a tariff-based transmission project on 19 November 2026 to evacuate power from the 2,400 MW Pirpainti thermal plant in Bihar, adding 881 circuit kilometres and about ₹500 crore of annual regulated revenue when the lines go live by late 2028.
Consumer durables / travel goods
VIP Industries is pushing premium luggage after two growth quarters
Managing director Atul Jain said on 19 November 2026 that VIP Industries grew consolidated revenue 15% in the September quarter, narrowed losses, and leaned on premium SKUs, roughly 65 new ranges, and wider retail reach while passing three price hikes totalling 7–8% in six months.
For informational purposes only. Not investment advice. Verify with filings and a licensed adviser.